{
  "id": "beae085398069b01",
  "title": "Best Weight Loss Pills for 2026 ? FDA Approves First Oral GLP - 1 as Patients Evaluate Wegovy , Zepbound , and Telehealth Access Pathways",
  "description": "Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access Shape Patient Choices as MEDVi Lists Compounded GLP-1 Programs Starting at $179, Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access Shape Patient Choices as MEDVi Lists Compounded GLP-1 Programs Starting at $179",
  "content": "mbid.marfeelrev.com\n\n# mbid.marfeelrev.com is blocked\n\nThis page has been blocked by an extension\n\n- Try disabling your extensions.\n\nERR\\_BLOCKED\\_BY\\_CLIENT\n\nReload\n\n\nThis page has been blocked by an extension\n\n![](<Base64-Image-Removed>)![](<Base64-Image-Removed>)\n\n![The Manila Times](https://cdn4.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1920&q=100&f=webp&v=1)\n\n![The Manila Times](https://www.manilatimes.net//theme_manilatimes/images/The_Manila_Times_400x53.png)\n\n[OPINION](https://www.manilatimes.net/opinion \"OPINION\")\n\n[NEWS](https://www.manilatimes.net/news \"NEWS\")\n\n[REGIONS](https://www.manilatimes.net/regions \"REGIONS\")\n\n[WORLD](https://www.manilatimes.net/world \"WORLD\")\n\n[BUSINESS](https://www.manilatimes.net/business \"BUSINESS\")\n\n[SPORTS](https://www.manilatimes.net/sports \"SPORTS\")\n\n[ENTERTAINMENT](https://www.manilatimes.net/entertainment-lifestyle/show-times \"ENTERTAINMENT\")\n\n[LIFESTYLE](https://www.manilatimes.net/entertainment-lifestyle/life-times \"LIFESTYLE\")\n\n[THE SUNDAY TIMES](https://www.manilatimes.net/the-sunday-times \"THE SUNDAY TIMES\")\n\n[SPECIAL FEATURES](https://www.manilatimes.net/supplements \"SPECIAL FEATURES\")\n\n[SPECIAL SECTIONS](https://www.manilatimes.net/special-sections \"SPECIAL SECTIONS\")\n\n[TMT NEWSWIRE](https://www.manilatimes.net/tmt-newswire \"TMT NEWSWIRE\")\n\n[Media OutReach Newswire](https://www.manilatimes.net/tmt-newswire/media-outreach-newswire \"Media OutReach Newswire\")\n\n[PR Newswire](https://www.manilatimes.net/tmt-newswire/pr-newswire \"PR Newswire\")\n\n[GlobeNewswire](https://www.manilatimes.net/tmt-newswire/globenewswire \"GlobeNewswire\")\n\n[Plentisoft](https://www.manilatimes.net/tmt-newswire/plentisoft \"Plentisoft\")\n\n[FAST TIMES](https://www.manilatimes.net/fast-times \"FAST TIMES\")\n\n[LEGAL ADVICE](https://www.manilatimes.net/legal-advice \"LEGAL ADVICE\")\n\n[CAMPUS PRESS](https://www.manilatimes.net/campus-press \"CAMPUS PRESS\")\n\n[VIDEOS](https://www.manilatimes.net/videos \"VIDEOS",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/30/tmt-newswire/globenewswire/best-weight-loss-pills-for-2026-fda-approves-first-oral-glp-1-as-patients-evaluate-wegovy-zepbound-and-telehealth-access-pathways/2250722",
  "published_at": "20251230T003000Z",
  "fetched_at": "2025-12-31T00:23:34.453563+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/30/tmt-newswire/globenewswire/best-weight-loss-pills-for-2026-fda-approves-first-oral-glp-1-as-patients-evaluate-wegovy-zepbound-and-telehealth-access-pathways/2250722",
    "url_mobile": "https://www.manilatimes.net/2025/12/30/tmt-newswire/globenewswire/best-weight-loss-pills-for-2026-fda-approves-first-oral-glp-1-as-patients-evaluate-wegovy-zepbound-and-telehealth-access-pathways/2250722/amp",
    "title": "Best Weight Loss Pills for 2026 ? FDA Approves First Oral GLP - 1 as Patients Evaluate Wegovy , Zepbound , and Telehealth Access Pathways",
    "seendate": "20251230T003000Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/30/882976.png",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}